BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas

Gastric Cancer

Volumn 7, Issue 4, 2004, Pages 246-253

  Wu, Ming ^a   Semba, Shuho ^a   Oue, Naohide ^b   Ikehara, Nobunao ^a   Yasui, Wataru ^b   Yokozaki, Hiroshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

BRAF; Gastric cancer; K ras; Microsatellite instability (MSI)

Indexed keywords

B RAF KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1;

ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CARCINOMA;

BASE PAIR MISMATCH; CARCINOMA; CARRIER PROTEINS; DISEASE PROGRESSION; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA REPAIR; GENES, RAS; HUMANS; MICROSATELLITE REPEATS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS B-RAF; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 12444269008     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-004-0300-9     Document Type: Article

References (49)

1. Barbacid M. ras genes. Annu Rev Biochem 1987;56:779-827.
2. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
3. Ellis CA, Clark G. The importance of being K-Ras. Cell Signal 2000;12:425-34.
4. Sills RC, Hong HL, Melnick RL, Boorman GA, Devereux TR. High frequency of codon 61 K-ras A→T transversions in lung and Harderian gland neoplasms of B6C3F1 mice exposed to chloroprene (2-chloro-1,3-butadiene) for 2 years, and comparisons with the structurally related chemicals isoprene and 1,3-butadiene. Carcinogenesis 1999;20:657-62.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54.
6. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
7. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
8. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002;62:7001-3.
9. Marais R, Marshall CJ. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv 1996;27:101-25.
10. Marshall CJ. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994;4:82-9.
11. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet 1997;13:444-9.
12. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
13. Razin A, Cedar H. DNA methylation and gene expression. Microbiol Rev 1991;55:451-8.
14. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-12.
15. Koinuma K, Shitoh K, Miyakura Y, Furukawa T, Yamashita Y, Ota J, et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 2004;108:237-42.
16. Kim IJ, Park JH, Kang HC, Shin Y, Park HW, Park HR, et al. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet 2003; 114:118-20.
17. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, et al. BRAF and KRAS mutations in stomach cancer. Oncogene 2003; 22:6942-5.
18. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003;22:9192-6.
19. Zhao W, Chan TL, Chu KM, Chan AS, Stratton MR, Yuen ST, et al. Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. Int J Cancer 2004;108: 167-9.
20. Mitra G, Pauly GT, Kumar R, Pei GK, Hughes SH, Moschel RC, et al. Molecular analysis of O6-substituted guanine-induced mutagenesis of ras oncogenes. Proc Natl Acad Sci U S A 1989;86: 8650-4.
21. Yanagihara K, Seyama T, Tsumuraya M, Kamada N, Yokoro K. Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res 1991;51:381-6.
22. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 1993;53:5815-21.
23. Hojo H. Establishment of cultured cell lines of human stomach cancer - origin and their morphological characteristics. Niigata Igaku Zasshi (Niigata Med J) 1977;91:737-52.
24. Ochiai A, Yasui W, Tahara E. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn J Cancer Res 1985;76:1064-71.
25. Oue N, Oshimo Y, Nakayama H, Ito R, Yoshida K, Matsusaki K, et al. DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci 2003;94:901-5.
26. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998;1:10-24.
27. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
28. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
29. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
30. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999;59:5438-42.
31. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003; 9:3362-8.
32. Uribe P, Wistuba II, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003;25:365-70.
33. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-7.
34. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404.
35. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62: 6451-5.
36. Lohr M, Maisonneuve P, Lowenfels AB. K-Ras mutations and benign pancreatic disease. Int J Pancreatol 2000;27:93-103.
37. Fong KM, Zimmerman PV, Smith PJ. KRAS codon 12 mutations in Australian non-small cell lung cancer. Aust NZJ Med 1998;28:184-9.
38. Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers - a review. Cancer Detect Prev 2000;24:1-12.
39. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 1995;55:2665-72.
40. Lee KH, Lee JS, Suh C, Kim SW, Kim SB, Lee JH, et al. Clinico-pathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer 1995;75:2794-801.
41. Miki H, Ohmori M, Perantoni AO, Enomoto T. K-ras activation in gastric epithelial tumors in Japanese. Cancer Lett 1991;58:107-13.
42. Carvalho B, Pinto M, Cirnes L, Oliveira C, Machado JC, Suriano G, et al. Concurrent hypermethylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. Eur J Cancer 2003;39:1222-7.
43. Fang DC, Wang RQ, Yang SM, Yang JM, Liu HF, Peng GY, et al. Mutation and methylation of hMLH1 in gastric carcinomas with microsatellite instability. World J Gastroenterol 2003;9:655-9.
44. Oue N, Sentani K, Yokozaki H, Kitadai Y, Ito R, Yasui W. Promoter methylation status of the DNA repair genes hMLH1 and MGMT in gastric carcinoma and metaplastic mucosa. Pathobiology 2001;69:143-9.
45. Oue N, Shigeishi H, Kuniyasu H, Yokozaki H, Kuraoka K, Ito R, et al. Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer 2001;93:805-9.
46. Park TJ, Han SU, Cho YK, Paik WK, Kim YB, Lim IK. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 2001;92:2760-8.
47. Pinto M, Oliveira C, Machado JC, Cirnes L, Tavares J, Carneiro F, et al. MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile. Lab Invest 2000;80:1915-23.
48. Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001;10:917-23.
49. Guidoboni M, Gafa R, Viel A, Doglioni C, Russo A, Santini A, et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001;159:297-304.